Symptoms and Clinical Signs of Hypogonadism in Testicular Cancer Survivors

Symptoms and Clinical Signs of Hypogonadism in Testicular Cancer Survivors

The purpose of this study is to investigate the prevalence of signs and symptoms of hypogonadism in three groups of testicular cancer survivors.

Recent studies have shown that metabolic syndrome is common among testicular cancer. Patients with low levels of testosterone appear to be at higher risk of metabolic syndrome.

A substantial number of testicular cancer survivors might be in a state of "compensated hypogonadism" with testosterone levels low in the normal range due to an increased LH-drive from the pituitary gland.

Whether this specific groups of testicular cancer survivors are at increased risk of cardio-vascular disease and might benefit from testosterone substitution is yet to be clarified.

Inclusion Criteria:

• Earlier treatment of testicular germ cell cancer
• No sign of relapse > 1 year since latest treatment
• Testosterone < 12 nmol/L and luteinizing hormone > 8 IE/L OR
• Testosterone > 12 nmol/L and LH > 8 IE/L OR
• Testosterone and LH within their normal ranges

Exclusion Criteria:

• Testosterone substitution